首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

2126601

肌萎縮側索硬化症 (ALS) 市場：按藥物類型、給藥途徑、劑型、分銷管道和地區分類

Amyotrophic Lateral Sclerosis (ALS) Market, By Drug Type, By Route of Administration, By Dosage Form, By Distribution Channel, By Geography

出版日期: 2026年08月14日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

肌萎縮側索硬化症（ALS）市場預計到 2026 年將達到 18.18 億美元，到 2033 年將達到 39.861 億美元。預計從 2026 年到 2033 年，該市場將以 11.9% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	18.18億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	11.90%	2033年市場規模預測：	39.861億美元

肌萎縮側索硬化症（ALS），又稱漸凍症，是一種進行性且致命的神經退化性疾病，其特徵是控制隨意肌運動的上運動神經元和下運動神經元退化和死亡。 ALS患者會出現肌肉無力、僵硬、肌肉痙攣以及言語、吞嚥和呼吸困難，最終導致癱瘓和呼吸衰竭。 ALS在男性中更為常見，主要發病年齡在40至70歲之間。 5%至10%的病例具有遺傳性，其餘病例為散發性。

全球肌萎縮側索硬化症 (ALS) 市場涵蓋治療、診斷、輔助技術以及旨在延緩疾病進展和緩解症狀的新型療法。隨著人們對該疾病的認知不斷提高、研究經費增加以及藥物研發的進步，該市場正蓬勃發展，這些因素推動了創新，並吸引了製藥公司、生物技術公司和醫療保健利益相關人員的注意。

市場動態

全球肌萎縮側索硬化症 (ALS) 市場成長的促進因素包括患者數量增加、疾病認知度提高以及診斷和治療方案的擴展。Riluzole和Edaravone等療法的出現，以及針對 SOD1 相關 ALS 的標靶治療（如托弗森）的出現，正在促進 ALS 研究領域的投資。

然而，肌萎縮側索硬化症（ALS）市場的成長受到諸多因素的限制，例如治療費用飆升、開發中國家保險報銷有限、該疾病複雜的生物機制以及臨床試驗的高失敗率。儘管如此，針對ALS相關突變（如SOD1、C9orf72、TARDBP和FUS）的基因研究進展正在推動精準醫療的發展，生物技術公司與學術機構之間的合作以及快速的法規核准流程正在加速有前景的療法的研發。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究基於以下參數分析了全球肌萎縮側索硬化症 (ALS) 市場的主要參與者：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份《全球肌萎縮側索硬化症（ALS）市場報告》旨在為該行業的各種相關人員提供服務，包括投資者、經銷商、產品製造商、分銷商、新參與企業和金融分析師。
相關人員可以透過分析全球肌萎縮側索硬化症 (ALS) 市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第9章競爭情勢

公司簡介
- Biogen Inc.
- Mitsubishi Tanabe Pharma Corporation
- Sanofi
- Otsuka Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Ionis Pharmaceuticals, Inc.
- AB Science
- BrainStorm Cell Therapeutics Inc.
- Clene Inc.
- Sun Pharmaceutical Industries Limited

第10章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第11章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9931

Amyotrophic Lateral Sclerosis (ALS) Market is estimated to be valued at USD 1,818.0 Mn in 2026 and is expected to reach USD 3,986.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 11.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,818.0 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.90%	2033 Value Projection:	USD 3,986.1 Mn

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive and fatal neurodegenerative disease characterized by degeneration and death of the upper and lower motor neurons that control voluntary muscle movements. ALS patients develop muscle weakness, stiffness, twitching and difficulty with talking, swallowing and breathing, eventually resulting in paralysis and respiratory failure. ALS is more common in males and affects mainly the age group of 40-70 years with 5-10% of cases being familial and the rest sporadic.

The global amyotrophic lateral sclerosis (ALS) market includes therapeutics, diagnostics, assistive technologies, and new pipeline therapies that seek to slow the disease progression and alleviate its symptoms. The market is gaining traction because of increased disease awareness, increased research funding, and advancements in drug development that are driving innovation and generating interest from pharmaceutical companies, biotechnology companies, and healthcare stakeholders.

Market Dynamics

The global amyotrophic lateral sclerosis (ALS) market is driven by increasing patient population, rising disease awareness, and increasing diagnosis and treatment. The availability of therapies like riluzole and edaravone, and the emergence of targeted therapies like tofersen for SOD1 associated ALS, are encouraging investments in ALS research.

However, the growth of amyotrophic lateral sclerosis (ALS) market is limited by factors such as high costs of treatment, limited reimbursement in developing economies, complex disease biology and high clinical trial failure rates. Nevertheless, advances in genetic research involving ALS-associated mutations such as SOD1, C9orf72, TARDBP, and FUS are supporting precision medicine development, while collaborations between biotechnology companies and academic institutions and expedited regulatory pathways are accelerating the development of promising therapies.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global amyotrophic lateral sclerosis (ALS) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen Inc., Mitsubishi Tanabe Pharma Corporation, Sanofi. Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Ionis Pharmaceuticals, Inc., AB Science, BrainStorm Cell Therapeutics Inc., Clene Inc., and Sun Pharmaceutical Industries Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global amyotrophic lateral sclerosis (ALS) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global amyotrophic lateral sclerosis (ALS) market

Market Segmentation

Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
Sodium Phenylbutyrate and Taurursodiol
Edaravone
Nuedexta
Tofersen
Riluzole
Muscle Relaxants
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Others
Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
Oral
Parenteral
Others
Dosage Form Insights (Revenue, USD Mn, 2021 - 2033)
Oral Suspension
Injectable
Tablets
Others
Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Regional Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Biogen Inc.
Mitsubishi Tanabe Pharma Corporation
Sanofi
Otsuka Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Ionis Pharmaceuticals, Inc.
AB Science
BrainStorm Cell Therapeutics Inc.
Clene Inc.
Sun Pharmaceutical Industries Limited

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Drug Type
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Route of Administration
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Dosage Form
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Distribution Channel
- Global Amyotrophic Lateral Sclerosis (ALS) Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Industry Trends

4. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Drug Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Sodium Phenylbutyrate and Taurursodiol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Edaravone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Nuedexta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Tofersen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Riluzole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Route of Administration, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Dosage Form, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Distribution Channel, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

8. Global Amyotrophic Lateral Sclerosis (ALS) Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Company Profile
- Biogen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Mitsubishi Tanabe Pharma Corporation
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sanofi
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Otsuka Pharmaceutical Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Eisai Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Ionis Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AB Science
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- BrainStorm Cell Therapeutics Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Clene Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sun Pharmaceutical Industries Limited
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies